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Summary 
Necroptosis and pyroptosis are inflammatory forms of regulated necrotic cell death as 
opposed to apoptosis that is generally considered immunologically silent. Recent 
studies revealed unexpected links in the pathways regulating and executing cell death 
in response to activation of signalling cascades inducing apoptosis, necroptosis and 
pyroptosis. Emerging evidence suggests that RIPK1 and caspase-8 control the cross-
talk between apoptosis, necroptosis and pyroptosis and determine the type of cell 
death induced in response to activation of cell death signalling. 
 
Introduction 
Cell death is an essential biological process for multicellular organisms including fungi, 
plants and animals [1], with important functions for development, tissue homeostasis 
and host defence. This article focuses on recent developments on cell death regulation 
and function in mice and humans with particular emphasis on the role of cell death in 
tissue homeostasis, inflammation and disease. Apoptosis was the first pathway of 
regulated cell death identified, initially described based on its distinct morphological 
features including cytoplasmic and nuclear condensation, membrane blebbing and the 
formation of apoptotic bodies. The discovery that apoptosis was induced by specific 
cysteinyl aspartate proteases termed caspases provided the proof that this type of cell 
death is controlled by distinct molecular machineries and should be considered a form 
of cellular suicide. Two pathways of apoptosis have been described based on the 
upstream initiator caspases that induce them [2]. Extrinsic apoptosis is induced by 
caspases 8 and 10, which are activated mostly in response to death receptor 
stimulation, while intrinsic apoptosis is induced by caspase-9, which is activated by 
cytochrome c released to the cytosol in response to mitochondrial outer membrane 
permeabilisation (MOMP). Initiator caspases activate the effector caspases 3, 6 and 
7, which proteolytically process multiple cellular substrates to induce the controlled 
demise of the cell [2]. 
Until recently, apoptosis was considered the only molecularly controlled type of cell 
death, as opposed to necrosis that was classically described as non-regulated 
accidental cell death. However, genetic, biochemical and functional evidence as well 
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as the discovery of specific chemical inhibitors of necrotic cell death have redefined 
necrosis as a molecularly controlled form of cell death [3,4]. Several types of regulated 
necrotic cell death have been recently identified, which share common morphological 
features, including increase of the cellular volume, swelling of organelles and 
disruption of the plasma membrane, but are activated in response to different triggers 
and are executed by distinct biochemical pathways [4]. Necroptosis is a form of 
regulated necrotic cell death induced by receptor interacting protein kinase 3 (RIPK3) 
and its substrate mixed lineage kinase-like (MLKL) [3]. RIPK3 is activated by upstream 
pathways via RIP homotypic interaction motif (RHIM)-dependent protein-protein 
interactions with the three additional proteins in the mammalian genome that contain 
conserved RHIMs, namely RIPK1, TRIF and ZBP1/DAI [3,5]. RIPK1 links RIPK3 to 
death receptor (DR) signalling, TRIF mediates RIPK3 activation downstream of TLR3 
and TLR4, whilst ZBP1/DAI mediates RIPK3 activation primarily in response to certain 
viruses [3,5]. Necroptosis execution requires the RIPK3-dependent phosphorylation of 
MLKL, which subsequently damages the plasma membrane via poorly understood 
mechanisms inducing the death of the cell [3,5].  
Pyroptosis is a type of regulated necrotic cell death induced by inflammatory caspases, 
namely caspase-1 as well as caspase-11 (in mouse cells) or caspase-4 and caspase-
5 (in human cells) [2]. Both caspase-1 and caspase-11 (or caspases-4, -5) induce 
pyroptosis by proteolytically processing Gasdermin D (GSDMD) yielding an N-terminal 
fragment that opens pores on the plasma membrane leading to cell death [6,7]. In 
addition to cleaving GSDMD, caspase-1 processes the precursor cytokines pro-IL-1b 
and pro-IL-18 to produce the mature bioactive forms that are released through the 
GSDMD pores and the lysed cells triggering inflammation [2]. Pyroptotic cell death is 
triggered by the assembly and activation of inflammasomes, macromolecular protein 
complexes that serve as platforms for the activation of caspase-1. The NOD-like 
receptors (NLRs) Nlrp3, Nlrp1b and Nlrc4, the cytosolic DNA sensor AIM2 (absent in 
melanoma 2) as well as Pyrin, engage the so-called canonical inflammasomes by 
recruiting and activating caspase-1 either directly or through the adaptor protein ASC 
(apoptosis-associated speck-like protein containing a CARD) [2].. The non-canonical 
inflammasome is triggered by intracellular lipopolysaccharide (LPS), which activates 
caspase-11 (caspase-4, -5 in human cells) [2]. 
These developments have sparked a large number of studies addressing the 
mechanisms regulating the different types of regulated cell death and their role in 
physiology and disease, which have been covered in a number of comprehensive 
reviews during the last years [3,5,8-10]. The aim of the present short article is not to 
comprehensively cover the large literature on cell death, but rather to discuss most 
recent studies that shed light on new mechanisms regulating and connecting 
necroptosis and pyroptosis, focusing particularly on the role of caspase-8 and RIPK1 
as essential players in a complex network of cell death signalling. 
 
RIPK1 regulation by ubiquitination and phosphorylation 
RIPK1 functions as a signalling hub within apoptotic and necroptotic cell death 
pathways and exhibits kinase-dependent and -independent functions that are 
important for the regulation of cell survival, cell death and inflammation. Studies in 
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genetic mouse models showed that RIPK1 acts as a scaffold independently of its 
kinase activity to prevent apoptosis and necroptosis in different tissues and that this 
function is important for preventing inflammation and maintaining tissue homeostasis 
[11-19]. Children with RIPK1 deficiency were found to suffer from severe 
immunodeficiency and autoinflammatory pathologies [20-22], suggesting that RIPK1 
scaffold functions are essential for tissue homeostasis also in humans. On the other 
hand, genetic and pharmacological inhibition of RIPK1 kinase activity revealed an 
important role of RIPK1 kinase-dependent apoptosis and necroptosis in driving 
inflammatory and degenerative pathologies in multiple tissues [23-30]. These studies 
highlighted the important but opposing roles of RIPK1 in preventing or promoting cell 
death and suggested that the balance between its kinase-independent and -dependent 
functions must be tightly regulated to ensure tissue homeostasis and prevent cell death 
and disease.  
Several studies revealed that ubiquitination of RIPK1 with lysine 63 (K63), K11, K48 
as well as M1 (linear) ubiquitin chains regulates its function by promoting its pro-
survival role within the TNFR1 signalling complex and preventing the formation of 
death-inducing protein complexes. In particular, the role of K63 and linear ubiquitin 
chains has been thoroughly investigated biochemically and genetically in numerous 
studies that could not be covered in this short article but have been discussed 
extensively in recent reviews [31-35]. Two recent studies revealed that mutation of 
lysine 376 of RIPK1, which was shown to be ubiquitinated by K63-linked chains [36], 
in murine RIPK1 caused embryonic lethality that was fully prevented by combined 
inhibition of caspase-8-mediated apoptosis and RIPK3-MLKL-dependent necroptosis 
[37,38], providing functional evidence that K376 (K377 in humans) is a critical residue 
for ubiquitin-dependent regulation of RIPK1. 
In addition to ubiquitination, multiple phosphorylation events are implicated in 
regulating RIPK1 function. Three independent studies reported that phosphorylation of 
RIPK1 by MK2 on multiple serine residues in the intermediate domain including serine 
321 in mouse (320 in human) restrains its kinase activity and cell death-inducing 
potential [39-41]. TAK1 was also suggested to mediate RIPK1 phosphorylation [42], 
but it remains unclear if this function of TAK1 is indirect by inducing MK2-dependent 
RIPK1 phosphorylation. Furthermore, RIPK1 phosphorylation by IkB kinases (IKKs) 
on multiple residues including serine 25 was reported to prevent RIPK1-mediated cell 
death [43]. Mutation of serine 25 of RIPK1 to glutamic acid to mimic phosphorylation 
indeed protected cells and mice from TNFR1-mediated cell death and inflammation by 
inhibiting RIPK1 kinase activity [44]. These reports revealed the important role of IKK-
mediated phosphorylation in preventing RIPK1-mediated cell death and inflammation, 
consistent with studies showing that mice with tissue specific knockout of IKK subunits 
developed inflammatory pathologies due to RIPK1-mediated cell death [26,29]. Two 
independent recent studies showed that TBK1 and IKKe also phosphorylate RIPK1 to 
suppress its cytotoxic potential [45,46], a function important during embryonic 
development as TBK1-deficient mice die between embryonic days 13.5 and 14.5 due 
to RIPK1 kinase dependent cell death [45]. Together, these studies revealed that 
RIPK1 ubiquitination and phosphorylation prevent the activation of RIPK1 kinase 
activity, which induces cell death by both apoptosis and necroptosis. 
Autophosphorylation is considered to be the critical function of RIPK1 kinase activity, 
with multiple residues identified as autophosphorylation sites in human (serines 14/15, 
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20, 161 and 166) and mouse (serines 14/15, 161 and 166 as well as threonine 169) 
RIPK1 [30,44,47,48]. Mechanistically, autophosphorylation is currently thought to 
impose a conformational change in RIPK1 facilitating the formation of the signalling 
complexes inducing apoptosis and necroptosis, however the specific function of 
individual autophosphorylation events remains to be experimentally validated in 
relevant in vivo models. 
  
Caspase-8 cleaves RIPK1 to prevent cell death and inflammation 
Caspase-8 inhibits necroptosis but the underlying mechanisms remain poorly 
understood. Caspase-8 was shown to cleave several proteins involved in the 
regulation of necroptosis, including RIPK1 [49], RIPK3 [50], CYLD [51] and cFLIP [52], 
however, the role of these cleavage events in the regulation of cell death and 
inflammation have remained unknown until recently. Four independent studies have 
now identified RIPK1 as a critical substrate that is cleaved by caspase-8 to prevent 
excessive cell death and inflammation [53-56] (Figure 1). In three of these studies, the 
authors generated knock-in mice expressing RIPK1 with mutation of aspartic acid at 
position 325 to alanine (D325A), which prevents its cleavage by caspase-8, and found 
that these mice died between embryonic days E10.5-E12.5 [53,55,56]. The embryonic 
lethality of Ripk1D325A/D325A mice could not be rescued by RIPK3 or MLKL deficiency but 
could be fully prevented by combined inhibition of FADD-caspase-8-mediated 
apoptosis and RIPK3-MLKL-mediated necroptosis [53,55,56], showing that caspase-
8-dependent cleavage of RIPK1 prevents both apoptosis and necroptosis. 
Interestingly, mice expressing RIPK1 with combined mutations inhibiting both its 
kinase activity (D138N) and caspase-8-mediated cleavage (D325A) developed to term 
but exhibited severe systemic inflammatory pathology resulting in early postnatal death 
[55,56], suggesting that inhibition of RIPK1 cleavage triggers cell death and 
inflammation by both kinase-dependent and -independent functions. Consistent with 
the genetic studies, mouse embryonic fibroblasts expressing RIPK1 with mutation of 
D325 underwent both apoptosis and necroptosis in response to TNF stimulation [54-
56]. Notably, patients with heterozygous missense mutations of the caspase-8 
cleavage site of human RIPK1 (D324) were reported to suffer from a syndrome 
characterised by periodic fever and lymphadenopathy [54,56], revealing that RIPK1 
cleavage by caspase-8 has a critical physiological role in preventing inflammation also 
in humans. Together, these studies identified RIPK1 cleavage by caspase-8 as a 
critical event that limits RIPK1-dependent cell death and inflammation in both mice and 
humans. Mechanistically, RIPK1 cleavage seems to limit apoptosis and necroptosis by 
dismantling the respective cell death inducing signalling complexes (Figure 1). 
 
Caspase-8 inhibits inflammasome activation 
In addition to its functions in inducing apoptosis and inhibiting necroptosis, recent 
studies revealed a novel role of caspase-8 in inhibiting inflammasome activation 
[57,58] (Figure 1). Knock-in mice expressing caspase-8 with mutation of its catalytic 
cysteine (C362) died at around embryonic day 10.5 similarly to mice lacking caspase-
8 or FADD [55,57,58]. However, while MLKL deficiency could rescue embryonic 
lethality and support survival of caspase-8 or FADD knockout mice to adulthood[59], 
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MLKL knockout could only prolong the survival of mice expressing catalytically inactive 
caspase-8 until birth [55,57,58]. This finding suggested that necroptosis-independent 
mechanisms caused perinatal death of mice expressing catalytically deficient caspase-
8. Formation of ASC specks was detected in tissues from these animals [57,58], 
suggesting that inflammasome activation could contribute to the pathology. Indeed, 
mice expressing catalytically inactive caspase-8 could survive to adulthood when 
crossed into combined Mlkl-/- Asc-/- or Mlkl-/- Caspase-1-/- genetic backgrounds [57,58], 
showing that ASC-Caspase-1-dependent mechanisms cause perinatal lethality in 
these mice. Furthermore, mice expressing catalytically inactive caspase-8 specifically 
in intestinal epithelial cells (IECs) were viable and showed mild intestinal inflammation, 
however when these mice were crossed into an Mlkl-/- genetic background they died 
perinatally and showed formation of ASC specks and expression of IL-1b in their 
intestines [57,58], suggesting that inhibition of necroptosis was detrimental by causing 
increased activation of the inflammasome. A rational interpretation of these results is 
that IECs expressing catalytically inactive caspase-8, which would normally undergo 
necroptosis, persist in the absence of MLKL and by mechanisms that depend on the 
presence of catalytically inactive caspase-8 but remain poorly understood ASC is 
activated inducing caspase-1-dependent inflammatory pathology. Interestingly, 
gasdermin D (GSDMD) deficiency could not rescue the Casp8C362A/C362A Mlkl-/- mice 
[57], suggesting that ASC and caspase-1 mediate the pathology by pyroptosis-
independent mechanisms. Moreover, RIPK3 deficiency could rescue mice expressing 
catalytically inactive caspase-8 to adulthood [57,58], suggesting that necroptosis-
independent functions of RIPK3 contribute to the activation of the ASC-caspase-1 
inflammasome. Taken together, these studies revealed another layer of cell death 
regulation controlled by caspase-8, which acts in a catalytic activity-dependent manner 
to restrain the activation of the ASC-caspase-1 inflammasome. Catalytically inactive 
caspase-8 acts as a scaffold to induce ASC-caspase-1 activation, though the 
underlying molecular mechanisms remain elusive. Interestingly, necroptosis seems to 
act as a mechanism inhibiting inflammation in the intestinal epithelium by limiting ASC-
caspase-1 activation by catalytically inactive caspase-8. Caspase-8-deficient patients 
were found to suffer from immune deregulation, lymphocytic infiltrations in multiple 
organs and very early onset inflammatory bowel disease [60-62], showing that 
caspase-8 has critical functions for the maintenance of immune homeostasis, in 
particular in the intestine, also in humans. 
 
Cross-talk between apoptosis, necroptosis and pyroptosis 
Despite the progress made in delineating the molecular machineries controlling and 
executing apoptosis, necroptosis and pyroptosis, the cross-talk between these cell 
death pathways has not been appreciated until lately. Recent findings provided 
evidence that these cell death pathways are interconnected at multiple levels and can 
be activated simultaneously or consecutively within the same cell (Figure 1). Caspase-
3, the executioner caspase in apoptosis, was shown to cleave and activate GSDME 
resulting in pyroptosis-like necrotic cell death in cells expressing sufficient amounts of 
GSDME [63,64], a phenomenon suggested to contribute to tissue damage in response 
to chemotherapeutic agents [63]. Caspase-8 was also recently suggested to cleave 
and activate GSDMD inducing pyroptosis in response to activation of the extrinsic 
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apoptosis signalling pathway [65-67]. An increased complexity of the regulation of 
GSDMD activation was revealed by experiments showing that caspase-3 cleaves 
GSDMD within its N-terminal domain thus limiting GSDMD-induced pyroptosis [65,68]. 
These studies revealed that apoptotic caspases such as caspase-8 and caspase-3 
can also trigger pyroptosis-like necrotic death in cells expressing GSDME and 
GSDMD, suggesting that the type of cell death induced is not determined by the 
caspases activated but by the availability of different caspase substrates that execute 
apoptotic or necrotic forms of cellular demise. 
A link between RIPK3-MLKL-induced necroptosis and NLRP3 inflammasome 
activation was suggested by studies showing that caspase-8 deficiency or treatment 
with caspase inhibitors caused NLRP3 activation that depended on RIPK3 and/or 
MLKL expression [69,70]. Although different mechanisms were proposed to explain 
this role of RIPK3 and MLKL, a recent study convincingly demonstrated that MLKL-
mediated permeabilisation of the plasma membrane triggers NLRP3 activation by 
inducing potassium efflux [71]. MLKL-dependent activation of the NLRP3 
inflammasome was shown to be physiologically important in mice with myeloid cell 
specific knockout of A20, where MLKL knockout could prevent NLRP3-Caspase-1-
dependent arthritis development [72]. Moreover, a number of studies reported that 
exposure of myeloid cells to agents promoting extrinsic or intrinsic apoptosis caused 
activation of NLRP3 resulting in inflammatory cell death [73-78], suggesting that 
apoptosis is also linked to inflammasome activation. Activation of the extrinsic and 
intrinsic apoptotic pathways was suggested to induce NLPR3 activation by activating 
pannexin-1 channel formation on the plasma membrane resulting in potassium efflux 
[65].  
 
Concluding remarks 
Together, the recent studies discussed here revealed new mechanisms regulating cell 
death, highlighting the complexity and plasticity of the pathways controlling if and how 
a cell dies. A key take home message is that cell death pathways do not operate in 
isolation as linear signalling cascades as often depicted in schematic models. On the 
contrary, the pathways regulating the different modalities of cell death are 
interconnected at multiple levels. The final outcome of a cell death inducing stimulus 
will depend on many parameters related to the expression and activation state of many 
factors that will determine if and how the cell dies. In certain cases, more than one cell 
death pathways may be induced in parallel influencing the immunogenic properties of 
the dying cells. This plasticity in simultaneously engaging diverse cell death pathways 
provides the cell with the capacity to fine-tune the cross-talk between dying and 
bystander cells in the tissue microenvironment and eliciting optimal responses 
ensuring effective tissue regeneration and host defence with minimal tissue damage. 
Elucidating the underlying mechanisms will be important in order to understand the 
role of cell death pathways in physiology and disease and exploit this knowledge for 
developing novel therapeutic approaches. 
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Figure 1. Caspase-8 regulates apoptosis, necroptosis and pyroptosis. 
Schematic depiction of the functions of caspase-8 in regulating apoptosis, necroptosis 
and pyroptosis. Left panel: caspase-8 acts as the initiator caspase in the extrinsic 
apoptosis pathway inducing activation of the effector caspases 3, 6 and 7 causing 
apoptotic cell death. GSDME cleavage by caspase-3 as well as GSDMD cleavage by 
caspase-8 can trigger lytic cell death resembling pyroptosis. Caspase-8 also inhibits 
necroptosis by cleaving RIPK1 and perhaps other proteins regulating necroptosis such 
as RIPK3. Right panel: loss of caspase-8 activity allows activation of necroptosis. 
Expression of catalytically inactive caspase-8 causes the activation of the 
ASC/caspase-1 inflammasome resulting in GSDMD-mediated pyroptosis. KD, kinase 
domain; DD, death domain; DED, death effector domain; R, RHIM; CARD, caspase 
recruitment domain; PYR, pyrin domain. 
 
 
